Inclusion Criteria:

- Age 18 years or older

- Mantle Cell Lymphoma according to REAL/WHO classification

- First or second relapse or alternatively progression during therapy. Previous use of
Bendamustine is permitted, if the patient has reached at least partial remission and
progression occured more than 6 months after therapy. Previous high dose chemotherapy
with auto-SCT is permitted, if the patient has reached at least partial remission and
progression occured more than 12 months after therapy.

- Patients must not be eligible for high dose chemotherapy with auto-SCT or allo-SCT.

- Adequate bone marrow function (hemoglobin > 9g/dl, platelet count >100/nL, absolute
neutrophil count >1,5 /nL)

- WHO/ECOG Performance Status 0-2

- Measurable disease (two perpendicular diameters by either physical or radiological
examination)

- Life expectancy ≥ 3 weeks

- Written informed consent

Exclusion Criteria:

- Prior treatment with any m-TOR Inhibitor

- Unstable or severe uncontrolled medical condition (e.g. severe congestive heart
failure, myocardial infarction within the past 6 months, severe, uncontrolled
arterial hypertension, renal insufficiency requiring hemodialysis, severe pulmonary
disease, severe diabetes)

- Abnormal liver function: transaminases or total bilirubin > 2 x upper limit of normal
(ULN)

- Abnormal renal function: serum creatinine > 2 x upper limit of normal

- Previous malignancy other than non-melanoma skin cancer or carcinoma in situ of the
cervix.

- Concurrent treatment with strong inhibitors of CYP3A4 and/or inducers of CYP3A4

- Pregnant or breastfeeding women (negative pregnancy test not older than 7 days is
required for women of fertile age). Men and women of child-bearing potential must
agree to use adequate contraception (i.e. failure rate < 1% p.a. )

- Major surgery within 4 weeks before study entry; minor procedures (e.g. Implantation
i.v. port catheter, Lymphnode biopsy) within 1 week before study entry

- Previous therapy with any investigational agents within 28 days before study entry

- Concomitant immunotherapy (e.g. Rituximab) or Chemotherapy other than Bendamustine.
Use of systemic steroids should be documented and the Principal Investigator be
informed.

- Central nervous system (CNS) lymphomatous involvement

- HIV positivity

- Current or chronic hepatitis B or hepatitis C infection

- Severe psychiatric illness or Individuals that are placed in an institution due to a
magisterial or judiciary command.

- Inability to comply with study requirements